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Smmmary In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with
advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxoteret). Six
patients were ineligible; of the 37 eligible patients, ten had prior radiotherapy and 18 prior surgery. They
received 00mg m2 in 1 h i.v. every 3 weeks, usually in an outpatient setting. Prophylactic steroids,
antihistaminics or antiemetics were not routinely given. Two patients were not evaluable because they
withdrew from the study because of a hypersensitivity reaction after the second cycle. The main toxicity was
neutropenia (80% of cycles), although infections were rare (4%). One patient died from sepsis during
neutropenia. Hypersensitivity reactions necessitating interruption of docetaxel (Taxotere) infusions were found
in only 10% of cycles. The overall response rate was 23% with one complete response, and seven partial
responses. Stable disease was found in 16 patients. The median duration of response was 36 weeks, and the
median survival of all patients was 11 months. Docetaxel (Taxotere.) is among the most active drugs for
treatment of NSCLC.
Lung cancer is now one of the leading causes of cancer death
in both men and women. The revised WHO histological
classification of lung tumours distinguishes four major cell
types, i.e. squamous cell carcinoma, adenocarcinoma and
large-cell and small-cell carcinoma. Non-small-cell lung
cancer (NSCLC) is a systemic disease in most cases; only
about 15-25% of unselected patients with these histological
types of lung cancers have anatomically localised disease
amenable to local treatment. Half of such patients die from
their disease despite local therapy with curative intent.
NSCLC is one of the tumour types in which single-agent
chemotherapy has been most extensively tested (Cohen &
Perevodchikova, 1979; Joss et al., 1984; Hansen et al., 1991).
Data suitable for analysis indicate that, by current standards,
response rates to single agents range from 5 to 20%. Detec-
tion of new and active agents for the treatment of NSCLC
therefore requires the continuing evaluation of novel subs-
tances in carefully selected patients with a good prognosis
and measurable disease.
In the late 1960s the National Cancer Institute's large-scale
plant screening programme found that a crude extract of the
bark from the Pacific yew, Taxus brevifolia, has activity
against P388 mouse leukaemia. In 1971, Paclitaxel (taxol)
was isolated and characterised as the active principle of the
extract (Wani et al., 1971). Docetaxel (Taxotere') is a
semisynthetic taxoid which has been synthesised from a
precursor extracted from a renewable natural source, the
needles of the European yew, Taxus baccata. It enhances
microtubule assembly and inhibits the depolymerisation of
tubulin. Docetaxel (Taxotere'l) had a favourable activity
profile when compared with taxol in animal models (Verweij
et al., 1994), and has therefore been selected for further
testing in human clinical trials.
We have conducted a prospective multicentre phase II trial
in order to determine the objective response rate and res-
ponse duration of docetaxel (Taxotere') in patients with
advanced NSCLC.
Paient and methods
Patients (see Table I) were eligible for study participation if
they had histologically or cytologically verified progressive
NSCLC. The tumour had to be locally advanced, unresec-
table or metastatic. The presence of a bidimensionally
measurable target lesion, a WHO performance status of < 2.
a life expectancy of > 12 weeks, WBC > 4.0 x I09 I-l and
platelets > 100 x l0O'1I as well as adequate renal and
hepatic function were obligatory. Exclusion criteria were
previous or concurrent chemotherapy, previous radiotherapy
to a site used to assess response, concurrent malignancy,
brain or leptomeningeal disease or concurrent treatment with
other experimental drugs. A thoracic CT scan was man-
datory at initial work-up. The sample size was determined
according to the Gehan method.
Follow-up studies included weekly complete blood counts
with differential, platelets and haemoglobin and 3-week
blood controls including biochemistry (AST, ALT, bilirubin,
LDH, serum creatinine, electrolytes, magnesium, alkaline
phosphatase, calcium, protein, albumin; urine analysis only if
indicated). For radiology a chest radiograph was required
every 3 weeks; furthermore, radiographs and ultrasound
scans of all measurable disease to assess response and
thoracic CT scans (only when sole means of evaluation) were
performed every two cycles. Additionally 3-weekly ECGs
were required.
The toxicity was graded using the NCI common toxicity
criteria (CTC).
Responses were classified according to the standard WHO
criteria. Assignment to the progression category was done 6
weeks after entry into the study. When progression was
observed between 3 and 6 weeks after entry into the study,
the patient was considered to be undergoing 'early progres-
sion'. Progression could not be defined prior to 3 weeks (one
full cycle) after entry into the study; patients removed from
the study at earlier times for whatever reason were con-
sidered non-evaluable for response.
Drug administration
Docetaxel (Taxotere') was given at a dose of 100 mg m-2 as
a 1 h intravenous infusion every 3 weeks in an outpatient
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Table I Patient characteristics (eligible patients: n = 37)
Performance status (WHO)
0
1
2
Sex
Male
Female
Age (years)
Median
Range
Histological subtype
Adenocarcinoma
Squamous cell carcinoma
Large-cell and other
undifferentiated NSCLC
Pretreatment
Surgery
Radiotherapy (18-56 Gy)
Tamoxifene
15
21
1
28
9
57
38-74
16
11
10
18
10
I
setting. Docetaxel (Taxotere') was diluted with 5% dextrose
or 0.9% saline to yield an intermediate solution of
I0mgml['. This solution was immediately shaken for 20s
using a mixer in order to obtain a clear solution. The appro-
priate amount of the drug to be administered was further
diluted in 5% dextrose or 0.9% saline to produce a maxi-
mum concentration of 1 mg ml1. The dose administered was
reduced to 75 mg m-2 in patients with haematological or
other toxicities. Reducing the dose by 25% of the previous
dose was necessary in case of a neutrophil nadir of
<0.5 x I01I-' lasting more than 7 days and/or with fever
(. 38.5'C) requiring i.v. antibiotics. The same reduction was
done in case of a platelet nadir of <25 x 1091-'. A treat-
ment delay of I week was mandatory if on day 22 the
neutrophil nadir was < 1.5 x 1091-. If no recovery was
achieved after I week, the patient was withdrawn from the
study.
Prophylactic steroids, antihistamines and antiemetics were
prohibited for the first cycle.
Guidelines for modification of the administration of
docetaxel in the cases of hypersensitivity reactions were as
follows. For mild symptoms, i.e. localised cutaneous reaction,
pruritus or flushing, the rate of infusion was to be decreased
until disappearance of symptoms. Docetaxel infusion was,
thereafter, completed. With moderate symptoms, such as
generalised pruritus, dyspnoea or hypotension (blood pres-
sure still above 80 mmHg), the infusion of docetaxel was to
be halted and antihistamines and i.v. corticosteroids were to
be given. The docetaxel infusion was to be resumed after
disappearance of symptoms. Premedication with cor-
ticosteroids and antihistamines was then optional in the
subsequent course of treatment. Bronchospasms, generalised
urticaria, hypotension with a systolic blood pressure of less
than 80 mmHg and angio-oedema were considered severe
symptoms, and if these occurred the docetaxel infusion was
stopped and antihistamines and steroids given. If possible,
the docetaxel infusion was resumed within 3 h after the
patient recovered and in this case premedication was man-
datory. Premedication was also necessary with subsequent
cycles and comprised dexchlorpheniramine i.v. 5-1O mg and
orally 5 mg and dexamethasone 5-10 mg i.v. and orally
20 mg, within 1 h before treatment.
In the case of grade 1 cutaneous reactions, according the
NCI common toxicity criteria, no dose modification resulted.
If grade 2 cutaneous reactions were observed, the subsequent
dose was reduced by 25%; in the case of grade 3 toxicity,
retreatment was delayed 1 week and then a dose modification
had to be applied.
Resuts
Forty-three patients were enrolled in the trial between May
and August 1992, 37 being eligible and evaluable for analysis.
Reasons for non-eligibility were: non-measurable lesions
(three patients), SCLC (one patient) and unstable cardiovas-
cular disease (one patient). In addition one patient was never
treated and had pre-existing significant neuropathy. There
were 28 male and nine female patients with a median age of
57 (38-74) years. Of the 37 eligible patients 15 had a WHO
performance status of 0, 21 were WHO grade I and one was
WHO grade 2. Prior surgery was performed in 18 patients
and prior radiotherapy in 10. One patient was pretreated
with tamoxifen. The histological subtype of NSCLC was
adenocarcinoma in 16 patients, squamous cell carcinoma in
11 patients, large-cell carcinoma in four patients and large-
cell undifferentiated or other undifferentiated NSCLC in ten
patients.
In total 167 cycles were administered (1-11 cycles per
patient); the median cumulative dose given was 325 mg m-2
per patient (range 100-1016 mg m -). The median dose
intensity (mg m-2 per week) was 29.9 (range 16.3-33.5).
Dose reductions were necessary in 46 (27%) of the 167
cycles: in 15 (9%) because of haematological toxicity, in 25
(15%) because of non-haematological toxicity and in six
(4%) for both reasons. Treatment delays were recorded in 13
(8%) of the cycles; in six (4%) this was drug related. Treat-
ment interruptions due to hypersensitivity were necessary in
16 (10%) of the 167 cycles.
Reasons for withdrawal from the study were disease pro-
gression in 18 patients, toxicity in seven (fluid retention in
two, hypersensitivity in two, asthenia in one, paraesthesia
and arthralgia in one, venous thrombosis at the injection site
in one), patient refusal in three, end of protocol in six,
intercurrent death in five.
Haematological toxicity (see Table II)
Significant leucopenia was found in 87% of the cycles and
neutropenia in 95% of the cycles, being CTC grade 3 and 4
in 62%. Febrile neutropenia occurred in nine cycles (5%);
proven infections were only seen in 4% of the cycles, while
on patient died from a neutropenia-related septicaemia.
Thrombocytopenia and anaemia, when they occurred, were
only mild.
Non-haematological toxicity (see Tables III and IV)
Complete hair loss occurred universally in all patients receiv-
ing two or more cycles. Skin toxicity was also common
(65%), but usually of mild to moderate severity. Symptoms
included pruritus, dry skin, erythema and desquamation.
Furthermore, nail changes consisting of calcification and/or
onycholysis were found in 22% ofpatients. Asthenia, malaise
and fatigue were encountered in 57% of the patients, and
diarrhoea in 13% of cycles. Weight gain, oedema and pleural
Table H Drug-related haematological toxicity per cycle (n = 167)
Common toxicity criteria I II III IV Total %
Leucopenia 24 56 57 9 146 87
Neutropenia 8 22 50 54 134 80
Anaemia 68 9 1 0 78 47
Thrombocytopenia 15 0 0 0 15 9
Table m Drug-related non-haematological toxicity per patient
(n = 37)
Common toxicity criteria I H III IVf NPK Total %
Alopecia 5 29 1 - - 35 95
Skin toxicity 8 11 2 1 2 24 65
Asthenia/malaise/fatigue 9 8 4 0 0 21 57
Neurological 11 3 0 0 0 14 38
Oedema 5 5 1 0 1 12 32
Pleural effusion 3 2 1 0 1 7 19
Weight gain 3 1 0 0 0 4 11
Nail changes/onycholysis 6 2b 0 0 0 8 22
aGrading not known. bOnycholysis.386 T. CERNY et al.
Table IV Most frequent drug-related non-haematological toxicity
per cycle (n= 167)
Common toxicity criteria I II III IV NA? Total %
Pain 14 10 4 0 0 28 17
Nausea 12 8 3 0 0 23 14
Diarrhoea 9 10 1 1 0 21 13
Fever 6 10 0 0 1 17 10
Allergy (hypersensitivity 7 6 4 0 0 17 10
response)
aGrading not known.
effusions were documented in 11%, 32% and 19% respec-
tively, the first symptoms occurring after a median
cumulative dose of 400 mgm2'. Allergy (hypersensitivity)
was seen in 30% of the patients and 10% of the cycles. It
was grade 3 in 11% of the patients but no grade 4 hypersen-
sitivity was seen. Mild fever was seen in 27%, vomiting in
16%, stomatitis in 13% and myalgia or headache in 11%.
Local phlebitis was found in 8%.
Neurological side-effects (38%), usually sensory neurotox-
icity (35%), were mostly mild and the symptoms are shown
in Table V. Pulmonary symptoms occurred in 30% of the
patients, but they were related to fluid retention or hypersen-
sitivity. CTC grade 3 and 4 pulmonary symptoms were found
in 8% of patients. Other toxicities only occurred infre-
quently.
Responses (see Table VI)
Two eligible patients did not receive two full cycles of treat-
ment because of hypersensitivity reactions, and were
therefore considered inevaluable for response. Of 35 patients
evaluable for response there was one complete remission
(3%) lasting 5 months. At that time adjuvant radiotherapy
was given, after which the patient has an ongoing response
for 14 months. Partial responses were seen in seven patients
(20%) and stable disease was found in 16 patients (46%). All
objective responses were subject to independent external
review. Eleven patients (31%) progressed during treatment.
Duration of response (complete, partial and no change) and
duration of survival were calculated from the commencement
of treatment. Patients were censored for duration of response
and time to progression at the date of further treatment. The
responses lasted 15-48 weeks with a median duration of
response according to the Kaplan-Meier method of 36
weeks (Figure 1). According to the same method the median
survival of evaluable patients was 11 months.
Dbusion
No widely tested single agent has a response rate of more
than 30% in NSCLC. Responses that do occur after single-
drug therapy are brief; complete remissions are rare. Ifos-
famide, vinblastine, etoposide, mitomycin C, cisplatin,
vindesine, vinorelbine and edatrexate are generally regarded
as being the most active agents. Several studies have shown
higher response rates to combination chemotherapy com-
pared with single agents. However, the combinations are not
necessarily associated with improved survival compared with
single agents, but they are universally associated with in-
creased toxicity. With currently available drug combinations,
the impact on survival in metastatic disease is to be regarded
as being modest. New agents and drug combinations are
needed to improve the prognosis of advanced NSCLC.
Docetaxcel (Taxcoteretm4) is a new promising drug for the
treatment of malignant diseases. The analysis of this phase II
Table V Specifications of neurological toxicity per cycle
(n= 167)
Comnmon toxiciav criteria I II III IV Total %
Sensory 33 4 0 0 37 22
Motor 3 1 0 0 4 2
Cortical 1 0 0 0 1 <1
Other (forehead 1 3 0 0 4 2
numbness)
Table VI Evaluation of response (WHO classification) (n =37)
Response n %
Complete remission 1 3
Partial remission 7 20
No change 16 49
Progression 11 29
Not evaluable 2
1.0
0.9 _
0.8 _
0.7
_ 0.6
X 0.5
o 0.4
L 0.3 Events = 5 (62%o)
0.2 - Censored = 3 (37%)
0.1 Median duration of response = 36 weeks
00 I1 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
Duration of response (weeks)
Fue 1 Duration of response, plotted according to the method
of Kaplan and Meier.
multicentre trial in patients in good clinical condition with
advanced, non-resectable or metastatic NSCLC reveals an
impressive activity of this novel taxoid. Docetaxel (Tax-
oterem), when given as a single drug at a dose of 100mg m 2
every 3 weeks on an outpatient basis, is generally well
tokrated. The dose-limiting toxicity in this schedule is short-
lasting leucopenia/neutropenia, rarely being associated with
infections. Other common toxicities are alopecia, skin tox-
icity, fatigue, nausea, neurological toxicity, diarrhoea, pain
and hypersensitivity reactions. Fluid retention, associated
with oedema, weight gain and pleural effusions, is another
common observation in patients treated with the agent at this
dose and schedule. One potentially treatment-related death
occurred in this series due to septicaemia during the second
cycle. Another patient died due to Candida tropicalis
pneumonia, after an episode of neutropenia had completely
resolved.
In a similar study, investigators at the Memorial Sloan-
Kettering Cancer Center reported a preliminary response rate
with docetaxel (Taxoteret) of 28% in 18 evaluable patients
with NSCLC (Rigas et al., 1993). Paclitaxel (Taxol) has also
been found to be active in non-small-cell lung cancer with a
response rate of 22% (Donehower & Rowinsky, 1993).
Further follow-up is needed to determine the definitive
response duration of this active and generally well-tolerated
new drug. The impact of concomitant steroids on the drug
profile of docetaxel (Taxoteretm) needs further evaluation.
The combination of docetaxel (Taxcoteretm4) with other active
agents for treatment of NSCLC, such as cisplatin or ifos-
famide, is presently under investigation.
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